PL EN


Preferences help
enabled [disable] Abstract
Number of results
2012 | 84 | 7 | 341-347
Article title

Vascular Endothelial Growth Factor and Survivin Immunostaining in Gastric Adenocarcinoma

Content
Title variants
Languages of publication
EN
Abstracts
EN
Two molecules - vascular endothelial growth factor involved in new vessels formation and survivin - antiapoptotic protein, reported to be associated with worse prognosis in various malignancies have been chosen for the study. Both are potential target for novel therapiesThe aim of the study was to determine the immunostaining of VEGF and survivin in gastric carcinoma and to analyse their relationship to the selected clinicopathological features and survival.Material and methods. Formalin-fixed, paraffin-embedded sections from 41 gastric adenocarcinomas were used for immunohistochemical reaction with monoclonal antibodies against vascular endothelial growth factor and survivin. The results were compared with selected clinicopathological features and survival.Results. Positive immunohistochemical reaction for vascular endothelial growth factor and survivin was revealed in 24 (58,53%) and 30 (73,17%), gastric carcinomas respectively. Vascular endothelial growth factor-negative gastric carcinomas were significantly more common in cases without metastases to regional lymph nodes and distant organs and in less advanced cases. Similar, distant metastases were also statistically less common in survivin-negative carcinomas. The differences in immunohistochemical reactions for survivin between less and more advanced cases almost reach statistical significance. The only factors significantly influenced 1, 2 and 3-year survival were vascular endothelial growth factor and survivin status. Statistically significant higher percentage of survival was noted in patients with vascular endothelial growth factor- and survivin-negative tumors.Conclusions. It seems that vascular endothelial growth factor and survivin play role in local invasion and spread of gastric adenocarcinoma and negatively influences survival. However, further studies are required to assess their true usefulness in the clinical practice.
Publisher

Year
Volume
84
Issue
7
Pages
341-347
Physical description
Dates
published
1 - 7 - 2012
online
30 - 8 - 2012
Contributors
  • Department of General Surgery, Hospital of Ministry of Interior in Lublin
  • Department of Clinical Pathomorphology, Medical University in Lublin
  • Department of General, Gastrointestinal and Oncological Surgery of the Alimentary Tract, Medical University in Lublin
  • Department of General, Gastrointestinal and Oncological Surgery of the Alimentary Tract, Medical University in Lublin
  • Department of Clinical Pathomorphology, Medical University in Lublin
  • Department of General, Gastrointestinal and Oncological Surgery of the Alimentary Tract, Medical University in Lublin
References
  • Meyer HJ, Wilke H: Treatment strategies in gastric cancer. Dtsch Arztelb Int 2011; 108: 698-706.
  • Wang TT, Qian XP, Liu BR: Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 2007; 13: 2784-90.[PubMed]
  • Yasiu W, Oue N, Kuniyasu H: Molecular diagnosis of gastric cancer: present and future. Gastr Cancer 2001; 4: 113-21.[Crossref]
  • Sun YS, Ye ZY, Zhao ZS: Expression of vascular endothelial growth factor C and survivin in gastric carcinoma and their clinical implications. Zhonghua Wei Chang Wai Ke Za Zhi 2006, 9: 264-67.
  • Iordache S, Saftoiu A, Georgescu CV et al.: Vascular endothelial growth factor expression and microvessel density - two useful tools for the assessment of prognosis and survival in gastric cancer patients. J Gastrointestin Liver Dis 2010; 19: 135-39.
  • Li YH, Wang C, Meng K: Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol 2004; 10: 1984-88.
  • Lauwers GY, Carneiro F, Graham DY et al.: Curado MP: Gastric carcinoma. W: Bosman FT, Carneiro F, Hruban RH, Theise ND (red.) WHO Classification of tumors of digestive system. Lyon: IARC 2010; s. 45-80.
  • Wang ZN, Xu HM, Jiang L: Expression of survivin in primary and metastatic gastric cancer cells obtained by laser capture microdissection. World J Gastroenterol 2004; 10: 3094-98.[PubMed]
  • Choi JH, Oh YH: Correlation of Vascular Endothelial Growth Factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma. J Kor Med Sci 2008; 23: 592-97.[WoS]
  • Dąbrowski A, Filip A, Zgodziński W et al.: Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 2004; 42: 169-72.
  • Li YH, Hu CF, Shao Q: Elevated expressions of survivin and VEGF protein are strong independent predictors of survival in advanced nasopharyngeal carcinoma. J Transl Med 2008; 6: 1.[PubMed][WoS][Crossref]
  • Lu CD, Altieri DC: Expression of a novel antiapoptosis gene, survivin correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12.
  • Jüttner S, Wissmann C, Jöns T: Vascular Endothelial Growth Factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. J Clin Oncol 2006; 24: 228-40.[PubMed]
  • Wallner G, Ciechański A, Dąbrowski A i wsp.: Znaczenie czynników bFGF i VFGF w surowicy krwi u chorych na raka żołądka. Pol Przegl Chir 2002; 74: 1138-44.
  • Song ZJ, Gong P, Wu YE: Relationship between the expression of iNOS, VEGF, tumor angiogenesis and gastric cancer. World J Gastroenterol 2002; 8: 591-95.[PubMed]
  • Abdou AG, Aiad H: Immunohistochemical evaluation of vascular endothelial growth factor (VEGF) in colorectal carcinoma. J Egypt Natl Canc Inst 2006; 18: 311-22.
  • Chen X, Li JS, Liang QP: Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl) 2008; 121: 881-86.
  • O'Connor DS, Schechner JS, Adida C: Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol 2000; 156: 393-98.[Crossref]
  • Prewett M, Santiago A, Oconnor W et al.: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209-18.
  • Yang JC, Haworth L, Sherry RW et al.: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34.[Crossref]
  • Gruchlik A, Chodurek E, Dzierewicz Z: VEGF-a target of antiangiogenic cancer therapy. Post Biol Kom 2007; 34: 557-80.
  • Polverini PJ, Leibovich SJ: Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984; 51: 635-42.[PubMed]
  • Xing Z, Conway EM, Kang C et al.: Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med 2004; 199: 69-80.
  • Plescia J, Salz W, Xia F et al.: Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005; 5: 457-68.[Crossref]
  • Akhtar M, Gallagher M, Lisa D: Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006; 13: 122-26.[PubMed][Crossref]
  • Miyachi K, Sasaki K, Onodera S: Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastr Cancer 2003; 6: 217-24.[Crossref]
  • Schultz IJ, Kiemeney LA, Witjes JA: Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23: 3327-31.[PubMed]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_v10035-012-0057-5
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.